Should terminally ill patients have the right to take dr... [BMJ. 2007] - PubMed

Should terminally ill patients have the right to take drugs that pass phase I testing? No. [BMJ. 2007]
Should terminally ill patients have the right to take drugs that pass phase I testing? No.
Gesme D. BMJ. 2007 Sep 8; 335(7618):479.
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society. [J Med Ethics. 2010]
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society.
Chahal M. J Med Ethics. 2010 Jun; 36(6):367-70. Epub 2010 May 28.
Review Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments. [Br Med Bull. 2009]
Review Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
Schüklenk U, Lowry C. Br Med Bull. 2009; 89:7-22. Epub 2008 Dec 3.
Ethics of large clinical trials in rapidly lethal diseases. [Lancet. 2003]
Ethics of large clinical trials in rapidly lethal diseases.
Rule S, Copplestone A. Lancet. 2003 Apr 12; 361(9365):1297.
Review [Recent proposals for early stage clinical trials of cancer]. [Gan To Kagaku Ryoho. 1994]
Review [Recent proposals for early stage clinical trials of cancer].
Ohashi Y. Gan To Kagaku Ryoho. 1994 Oct; 21 Suppl 3:292-4.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC

Should terminally ill patients have the right to take drugs that pass phase I te...
Should terminally ill patients have the right to take drugs that pass phase I testing? Yes.
BMJ. 2007 Sep 8 ;335(7618):478.

PubMed
The investigational new drug application--who benefits?
The investigational new drug application--who benefits?
Nat Clin Pract Oncol. 2006 Feb ;3(2):62-3.

PubMed
Establishment of baseline toxicity expectations with standard frontline chemothe...
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood. 2007 Nov 15 ;110(10):3547-51. Epub 2007 Aug 2 .

PubMed
Metastasis--an alternative hypothesis.
Metastasis--an alternative hypothesis.
Cancer. 2005 Apr 15 ;103(8):1537-9.

PubMed
Hydration assessment techniques.
Hydration assessment techniques.
Nutr Rev. 2005 Jun ;63(6 Pt 2):S40-54.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed